Eurotox 2009 - Dresden, Germany 

Symposium 6 (WHO/International Programme on Chemical Safety) Tuesday, September 15

The increasing use of pharmacokinetic models in chemical risk assessments is recognised. It is necessary to develop a common understanding of what constituents are required to develop an internationally acceptable model and how to validate it. A common understanding would facilitate sharing of models and model evaluations as well as consistent application in risk assessments. Consideration will be given to:

1) Model development,
2) Model characterization, i.e. methods to describe how consistent the model is with biology; strengths and limitations of available model and data, such as sensitivity analyses,
3) Model documentation,
4) Model evaluation, i.e. independent review.

Presentations by

Dr. Bette Meek, Canada, Prof. Dr. Ursula Gundert-Remy, Germany, Dr. George Loizou, UK, Dr. Harvey J. Clewell III, USA, Dr. Olavi Pelkonen, Finland